Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 16, 2008. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction rather than general financial performance.
Material Changes
The only material change reported is an increase in the interest of Dr. R G Greig in Ordinary Share ADRs. This increase resulted from the re-investment of a dividend paid to shareholders on January 10, 2008, at a price of $54.11 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: January 16, 2008.
- Individual Involved: Dr. R G Greig.
- Transaction Type: Increase in Ordinary Share ADRs via dividend re-investment.
- Price per ADR: $54.11.
- Dividend Payment Date: January 10, 2008.